8096 Background: While potentially targetable genomic alterations have been identified in squamous NSCLC, none have yet been translated into effective therapy. The NCI LungMAP study was designed to match patients (pts) with advanced squamous NSCLC to genotype selected treatment using targeted NGS. We studied a large cohort of consecutive pts with squamous NSCLC to gauge the feasibility of NGS for clinical trial arm allocation. Methods: All patients presenting to the Dana-Farber Cancer Institute are offered targeted NGS of existing biopsy samples under an institutional protocol (#11-104). This internally developed NGS assay sequences over 300 genomic targets of interest with a mean overall target coverage of 200x. All squamous NSCLC pts seen at our institution during the study period were identified from an institutional database. The rate of test utilization, assay failure, and detected genomic alterations were studied. Results: 174 pts with squamous NSCLC presented to our institution from 7/1/2013-11/18/...